PROF. PAUL R KNIGHT, M.D., PH.D
Anesthesiologist Assistant in Buffalo, NY
License number
New York 191434-1
Category
Osteopathic Medicine
Type
Anesthesiology
Address
Address
2
3495 Bailey Ave Vhawny ROOM 203C, Buffalo, NY 14215
2416 W Oakfield Rd, Grand Island, NY 14072
2416 W Oakfield Rd, Grand Island, NY 14072
Phone
(716) 862-8706
(716) 862-8709 (Fax)
(716) 774-8470
(716) 862-8709 (Fax)
(716) 774-8470
Personal information
See more information about PAUL R KNIGHT at radaris.comName
Address
Phone
55 Highland Rd, Rye, NY 10580
375 Seaford Ave, Massapequa, NY 11758
408 E 54Th St, Brooklyn, NY 11203
Professional information
Paul R Knight, Buffalo NY
Specialties:
Anesthesiologist
Address:
3495 Bailey Ave, Buffalo, NY 14215
Education:
Pennsylvania State University, College of Medicine - Doctor of Medicine
Children's Hospital - Residency - Anesthesiology
Children's Hospital - Residency - Surgery
Children's Hospital - Residency - Anesthesiology
Children's Hospital - Residency - Surgery
Board certifications:
American Board of Anesthesiology Certification in Anesthesiology
Independent Information Technology And Services Professional
Location:
Buffalo/Niagara, New York Area
Industry:
Information Technology and Services
Viral Therapy And Prophylaxis Using Nanotechnology Delivery Techniques
US Patent:
2012000, Jan 12, 2012
Filed:
May 6, 2011
Appl. No.:
13/102808
Inventors:
Krishnan Chakravarthy - Williamsville NY, US
Suryaprakash Sambhara - Atlanta GA, US
Paul Knight - Grand Island NY, US
Suryaprakash Sambhara - Atlanta GA, US
Paul Knight - Grand Island NY, US
Assignee:
NANOAXIS - Williamsville NY
International Classification:
A61K 31/713, A61P 31/12, C07H 21/02, A61K 9/12, B82Y 5/00
US Classification:
424 43, 536 245, 536 231, 514 44 A, 977774
Abstract:
The present disclosure provides compositions and methods of enhancing resistance to viral infections through targeted delivery of 5′PPP negative stranded siRNA via nanoparticles, specifically gold nanorods. The 5′PPP activates type I interferon through the signaling cascade providing a novel therapeutic and prophylactic for seasonal and pandemic influenza. The technology described herein also extends the findings to the use of nanoparticles for delivery of genetic material including but not limited to siRNA and microRNA to accomplish targeted nanoparticle based gene therapy.